RomanPerez-SolerMD

PubMed

• 34 citations
  Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell li...
  Yi He Ling, Miguel Aracil, José Enrique Garzón Jimeno, Roman Perez-Soler, Yiyu Zou
  European Journal of Cancer. 2009-07-01
• 86 citations
  Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
  Roman Perez-Soler, Frank V. Fossella, Bonnie S. Glisson, Jangsoon Lee, William K. Murphy
  Journal of Clinical Oncology. 1996-02-01
• 537 citations
  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.
  Vikas Mehta, Sanjay Goel, Rafi Kabarriti, Daniel Cole, Mendel Goldfinger
  Cancer Discovery. 2020-05-01

Journal Articles

• Aerosol azacytidine inhibits orthotopic lung cancers in mice through its DNA demethylation and gene reactivation effects  
  Qiu X, Liang Y, Sellers R, Verma A, Perez-Soler R, Zou Y, PLoS ONE, 1/1/2014
• Talactoferrin alfa versus placebo in patients with refractory advanced non-small cell lung cancer (FORTIS-M trial)  
  Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, et al, Ann Oncol, 1/1/2013
• Role of erlotinib in the treatment of NSCLC: clinical outcomes in wild-type EGFR patients  
  Piperdi B, Perez-Soler R, Drugs, 1/1/2012
• Phase I/II study of bortezomib in combination with carboplatin and bevacizumab as first line therapy in patiernts with advanced non-small cell lung cancer  
  Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L, Perez-Soler R, J Thoracic Oncol, 1/1/2012
• Mechanisms of Resistance to VEGF Blockade  
  Abdullah SE, Perez-Soler R, Cancer, 1/1/2011
• Both gene amplification and allelic loss occur at 14q133 in lung cancer  
  Lutz D, Tian J, Kajiyama Y, Sapkar J, Perez-Soler R, Keller S, Lopez-Barcons L, Locker J, Clin Cancer Res, 1/1/2011
• Bortezomib: understanding the mechanism of action  
  Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R, Mol Cancer Ther, 1/1/2011
• Treatment of non-small cell lung cancer with erlotinib or gefitinib  
  Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A, New Engl J Med, 1/1/2011
• Intratracheal administration of 5-azacitidine avoids systemic toxicity and enhances antitumor efficacy in orthotopic human NSCLC xenograft models  
  Mahesh S, Ling Y, Perez-Soler R, Zou Y, Clin Lung Cancer, 1/1/2010
• Intercalation of erlotinib and pemetrexed in the treatment of NSCLC  
  Li T, Lara PN, Mack PC, Perez-Soler R, Gandara DR, Curr Drug Targets, 1/1/2010
• EGFR TKI’s for advanced NSCLC: practical questions  
  Perez-Soler R, Oncology, 1/1/2010
• Phase II study of the proteasome inhibitor bortezomib (PS 341, velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)  
  Li T, Ho L, Piperdi B, Macapinlac M, Rigas J, Camacho FJ, Perez-Soler R, Gucalp R, J Thoracic Oncology, 6/11/2009
• Tunicamycin enhances the sensitivity of human NSCLC cells to erlotinib  
  Ling, YH, Li T, Perez-Soler R, Haigentz M, Cancer Chemother Pharmacol, 1/1/2009
• Molecular pharmacodynamics of Irvalec® as single agent and in combination with Erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenog...  
  Ling Y, Aracil M, Perez-Soler R, Zou Y, Eur J Cancer, 1/1/2009
• Individualized therapy in NSCLC: future vs current clinical practice  
  Perez-Soler R, Oncogene, 1/1/2009
• Skin toxicities associated with epidermal growth factor inhibitors  
  Li T, Perez-Soler R, Target Oncology, 1/1/2009
• PI3KCA/PTEN mutation status predicts response of colon cancer cells to the EGFR inhibitor cetuximab  
  Jhawer M, Goel S, Ling YH. Augenlicht L, Perez-Soler R, Mariadason J, Cancer Res, 1/1/2008
• Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human NSCLC cells expressing wild type EGFR gene  
  Li T, Ling YH, Perez-Soler, R, J Thoracic Oncology, 1/1/2008
• Erlotinib induces apoptotsis via mitochondria-mediated pathways by oxidative phosphorylation-dependent activation of Bax/Bak  
  Ling YH, Haigentz M, Perez-Soler R, Mol Pharmacol, 1/1/2008
• Erlotinib, an effective EGFR tyrosine kinase inhibitor induces p27KIPI upregulation and nuclear translocation in association with cell growth inhibition and cell cycle...  
  Ling YH, Li T, Yuan Z, Haigentz M, Weber TK, Perez-Soler R, Mol Pharmacol, 4/24/2007
• Targeting protein translation in human NSCLC via combined MEK and mTOR suppression  
  Legrier ME, Yang CPH, Yan HG, Lopez-Barcons L, Keller SM, Perez-Soler R, Horwitz S, McDaid H, Cancer Res, 1/1/2007
• Development of an aerosol formulation of the p53 gene with low toxicity and high efficacy in the treatment of early lung cancer  
  Zou Y, Tornos C, Qiu X, Lia M, Perez-Soler R, Clin Cancer Res, 1/1/2007
• Erlotinib: recent results and future developments  
  Perez-Soler R, Clin Cancer Res, 1/1/2007
• Novel agents in the treatment of lung cancer: Fourth Cambridge Conference  
  Lynch TJ, Bonomi PD, Butts C, Perez-Soler R, et al, Clin Cancer Res, 1/1/2007
• Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung  
  Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicolson S, Peters GJ, Postmus PE, Clin Cancer Res, 1/1/2007
• Join now to see all

Books/Book Chapters

• Malignant Mesothelioma. 
  Chapter: Intracavitary therapies for malignant pleural mesothelioma. 
  Page 631 - 637Piperdi B, Shin DM, Perez-Soler REditors: Pass HI, Vogelzang NJ, Carbone M.Springer, New York, NY2005
• Lung Cancer, Methods in Molecular Medicine Series 
  Chapter: Chemopreventive therapeutics: Inhalation therapies for lung cancer and bronchial premalignancy. 
  Page 771 - 780Haigentz M, Perez-Soler REditors: Driscoll B.Humana Press, Totowa, NJ2002
• Cancer Treatment 
  Chapter: Investigational drugs. 
  Page 475 - 482Perez-Soler R, Muggia FMEditors: Haskell CM.W.B. Saunders Company, Philladelphia, PAEdition 5th,2001
• Medical Applications of Liposomes. 
  Chapter: Liposomes as carriers of hydrophobic antitumor agents. 
  Page 283 - 296Perez-Soler R, Zou YEditors: Lasic DD, Papahadjopoulos D.Elsevier1998
• Lung Cancer. 
  Chapter: Growth factors receptors as a target for therapy. 
  Page 309 - 341Perez-Soler R, Mendelsohn JEditors: Roth JA, Cox JD, Hong WK.Blackwell Science, Inc., Cambridge, MA1998
• EGF Receptor in tumor growth and progression. 
  Chapter: Epidermal growth factor receptor expression in head and neck tumorigenesis and saturation of EGFR with monoclonal antibody RG83852. 
  Shin DM, Perez-Soler R, Hittelman WN, Hong WKEditors: RB Lichtner, and RN Harkins.Springer-Verlag, Heidelberg1997
• Carbohydrates: Targets for Rational Drug Design. 
  Chapter: Sugar-modified anthracyclines: a search for drugs able to overcome multidrug resistance. 
  Priebe W, Perez-Soler REditors: Z.J. Witczak and K.A. Nieforth.Marcel Dekker Inc., New York, NY1996
• Anthracycline antibiotics: new analogs, methods of delivery and mechanisms of action. 
  Chapter: Non-cross resistant anthracyclines with reduced basicity and increased stability of the glycosidic bond. 
  Page 14 - 46Priebe W, Skibicki P, Varela O, Neamati N, Sznaidman M, Dziewiszek K, Grynkiewicz G, Horton D, Zou Y, Ling YH, Perez-Soler REditors: Priebe W.ACS Symposium, Washington, DC1995
• Anthracycline antibiotics: new analogs, methods of delivery and mechanisms of action. 
  Chapter: Use of drug carriers to ameliorate the antitumor properties of anthracycline antibiotics. 
  Page 300 - 319Perez-Soler R, Sugarman S, Zou Y, Priebe WEditors: Priebe W.ACS Symposium, Washington, DC1995
• Liposome-mediated cancer chemotherapy. 
  Chapter: The use of liposomes as delivery vehicles in biological systems. 
  Perez-Soler REditors: Sugarman S and Perez-Soler R.R.G. Landes Company, Austin, TX1995
• Drug Targeting and Delivery, Vol 2: Liposomes in drug delivery. 
  Chapter: Development of new lipophilic anticancer agents entrapped in liposomes. 
  Page 1 - 9Perez-Soler R, Khokhar AR, Priebe W, Krakoff IHEditors: Gregoriadis G, Florence AT and Patel HM.Harwood Academic Publishers, Chur, Switzerland1993
• Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. 
  Chapter: Pharmacological studies with new liposome-entrapped cisplatin derivatives. 
  Page 377 - 390Perez-Soler R, Siddik ZH, Vadiei K, Krakoff IH, Khokhar AREditors: Howell SB.Plenum Publishing Corporation, New York, NY1991
• From the bench to the bed side. Proceedings of the 16th International Congress of Chemotherapy 
  Chapter: Development of liposome entrapped platinum compounds. 
  Perez-Soler R, Khokhar ARJerusalem, Israel1989
• Liposomes in the treatment of infectious diseases and cancer. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 89. 
  Chapter: Design and development of liposome dependent antitumor agents. 
  Page 59 - 69Perez-Soler R, Lopez-Berestein G, Khokhar AREditors: Lopez-Berestein G, I Fidler.Alan Liss, Inc., New York, NY1988
• Liposomes as Drug Carriers. 
  Chapter: Development of lipophilic cisplatin analogues encapsulated in liposomes. 
  Page 401 - 417Perez-Soler R, Khokhar AR, Lopez-Berestein GEditors: G Gregoriadis.John Wiley & Sons, Ltd, United Kingdom1988
• Anticarcinogenesis and Radiation Protection. 
  Chapter: Prospects of Liposomes as Drug Carriers. 
  Page 441 - 450Lopez-Berestein G, Perez-Soler REditors: PA Cerutti, OF Nygaard, and MG Simic.Plenum Press, New York and London1987
• Join now to see all

Abstracts/Posters

• Role of EGFR inhibitors in the treatment of BAC. Oral Presentations Discussion
  Perez-Soler R, Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 6/1/2004

Lectures

• Demethylating Theerapy for Lung Cancer 
  Cancun, Mexico - 5/1/2014
• New Therapies for Lung Cancer 
  Mount Sinai School of Medicine - 3/1/2014
• Inhaled demethylating therapy. 
  Santa Barbara, CA - 2/1/2014
• 7th Annual New York Lung Cancer Symposium 
  Physicians' Education Resource, LLC, New York, New York - 11/10/2012
• The Molecular Biology of Lung Cancer 
  Fox Chase Cancer Center, Philadelphia, PA - 12/1/2011
• Maintenance and Frontline Therapy of NSCLC. 
  Sun Peaks, British Columbia, Canada - 2/1/2011
• Extending Survival with Erlotinib in NSCLC. 
  Seoul, South Korea - 12/1/2010
• Reversible EGFR inhibitors. 
  New York, NY - 11/1/2010
• Maintenance therapy in NSCLC: which agent? which patients? 
  New York, NY - 11/1/2010
• Advances in the treatment of NSCLC. 
  Rabin Medical Center, Hadassah Ein Kerem Medical Center, Israel - 11/1/2010
• Mechanisms of resistance to EGFR inhibitors. 
  Marbella, Spain - 6/1/2010
• Advances in Lung Cancer treatment. 
  Bologna, Italy - 6/1/2010
• Rationale for maintenance therapy in NSCLC. 
  Shanghai, China - 3/1/2010
• Use of biomarkers in lung cancer therapy. 
  Columbia College of Physicians and Surgeons, New York Presbyterian Hospital - 1/1/2010
• Breaking ground in the frontline treatment of NSCLC. 
  Hong Kong, China - 11/1/2009
• Mecanisms of resistance to EGFR inhibitors. 
  New York, NY - 11/1/2009
• Managament of skin toxicities secondary to EGFR inhibitors. 
  11/1/2009
• The Molecular Biology of Cancer 
  Ann Arbor, MI - 10/1/2009
• Management of side effects with new molecular therapies for NSCLC. 
  San Francisco, CA - 7/1/2009
• Advances in NSCLC treatment. 
  Roswell Park Memorial Institute - 7/1/2009
• How to get a Clinical RO1 grant? 
  Orlando, FL - 6/1/2009
• c-MET inhibitors in NSCLC. 
  HI - 6/1/2009
• Update on anti-EGFR monoclonal antibodies in the treatment of NSCLC. 
  HI - 6/1/2009
• What is new in second line therapy for NSCLC? 
  HI - 6/1/2009
• Advances in adjuvant therapy for NSCLC. 
  Fortaleza, Brazil - 2/1/2009
• Join now to see all

Other

• In vivo chemosensitivity screen for human tumors. 
  Perez-Soler R, US Patent 6,620,403
  9/16/2003
• Cryogenic and ultrasonic system and method of use in treating and removing tissue. 
  Kelman CD, Perez-Soler, R, US Patent 6,527,765 B2
  3/4/2003
• Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents. 
  Priebe, W, Perez-Soler, R, US Patent 6,437,105
  8/20/2002
• Submicron liposome suspensions obtained from preliposome lypophilizates. Licensed to Callisto Pharmaceuticals Inc, New York. In clinical development. 
  Zou Y, Priebe W, Perez-Soler R, US Patent 5,902,604
  5/11/1999
• Bis-anthracyclines with high activity against doxorubicin-resistant tumors. 
  Priebe W, Chaires JB, Przewloka T, Fokt I, Perez-Soler R, US Patent 5,874,412
  2/23/1999
• Formulation and use of carotenoids in the treatment of cancer. Licensed to Antigenics, Inc, New York. In clinical development. 
  Mehta K, Perez-Soler R, Lopez-Berestein G, Lenk RP, Hayman A, European Patent 0621773
  11/25/1998
• The liposomal entrapment of camptothecin. 
  Sugarman S, Poirot K, Perez-Soler R, US Patent 5,834,012
  11/10/1998
• Gene therapy of tumors using a non-viral delivery system. Filed, Claims allowed, Licensed to Transave Inc. Princeton, NJ 
  Zou Y, Perez-Soler, R
  1/6/1998
• Anthracyclines with unusually high activity against cells resistant to doxorubicin and analogs. 
  Priebe W, Skibicki P, Perez-Soler R, US Patent 5,625,043
  4/29/1997
• Stable liposomal formulations of lipophilic platinum compounds. Licensed to Antigenics Inc, New York. In clinical development. 
  Perez-Soler R, Khokhar AR, Han I, U.S. Patent 5,384,127
  1/24/1995
• Esters of 3'-desamino-doxorubicin, liposomal compositions thereof, and methods for their use. 
  Priebe W, Perez-Soler R, U.S. Patent 5,132,290
  7/21/1992
• Hydrophobic cis-platinum complexes efficiently incorporated into liposomes. 
  Khokhar AR, Lopez-Berestein G, Perez-Soler R, U.S. Patent 5,041,581
  8/20/1991
• Liposome compositions of anthracycline derivatives. 
  Perez-Soler R, Priebe W, Lopez-Berestein G, U.S. Patent 4,863,739
  9/5/1989
• Treatment of skin toxicity caused by EGFR inhibitors with phosphatase inhibitors. Licensed to Talon Therapeutics, South San Francisco, CA. In Phase II clinical develo... 
  Perez-Soler R, Ling YH, US Patent 7,745,494
• Join now to see all